<DOC>
	<DOCNO>NCT02921802</DOCNO>
	<brief_summary>To understand safety efficacy RevlimidÂ® 5 mg Capsules ( hereinafter refer Revlimid ) patient treat actual condition use pursuant condition approval . 1 . Planned registration period This period start date initial marketing Revlimid end time plan number patient enrol reach . 2 . Planned surveillance period This period start date initial marketing Revlimid end day approval condition relate all-case surveillance terminate .</brief_summary>
	<brief_title>A Study Special Use Results Surveillance Revlimid 5mg Capsules</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Among relapsed refractory multiple myeloma Myelodysplastic syndrome ( MDS ) deletion 5q cytogenetic abnormality patient , patient receive Revlimid target surveillance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Teratogenicity</keyword>
	<keyword>Thrombocytopenia haemorrhage</keyword>
	<keyword>Neutropenia infection</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Allergic reaction</keyword>
	<keyword>Diarrhoea constipation</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Cardiac failure</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Tumour lysis syndrome</keyword>
	<keyword>Transformation myelodysplastic syndrome acute myeloid leukemia</keyword>
</DOC>